. Author manuscript; available in PMC: 2024 Jun 20.

Published in final edited form as: Clin Cancer Res. 2023 Jan 4;29(1):110–121. doi: 10.1158/1078-0432.CCR-22-2235

Table 3.

Best overall response in patients receiving weekly (Group A) and monthly (Group B) treatment schedule.

	Group A N = 67	Group B N = 39	All patients N = 106

Best overall response, n (%)
Complete response	1 (1.5)	0	1 (0.9)
Partial response	8 (11.9)	2 (5.1)	10 (9.4)
Stable disease	11 (16.4)	9 (23.1)	20 (18.9)
Progressive disease	34 (50.7)	22 (56.4)	56 (52.8)
Non-CR/Non-PD	1 (1.5)	0	1 (0.9)
Unknown	12 (17.9)	6 (15.4)	18 (17.0)
Overall response rate (CR or PR), n (%)	9 (13.4)	2 (5.1)	11 (10.4)
90% CI	7.2–22.3	0.9–15.3	5.9–16.6
Disease control rate (CR, PR, or SD), n (%)	20 (29.9)	11 (28.2)	31 (29.2)
90% CI	20.7–40.4	16.7–42.3	22.0–37.4

Abbreviations: CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.